ChromaDex® Corp. (CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure®, announced today the award of two method validation study contracts from the Office of Dietary Supplements (ODS), National Institutes of Health (NIH). These awards were made as part of the contract ChromaDex has with the General Services Administration (GSA) -- Schedule 66: Scientific Equipment and Services, SIN 873-2: Chemical Testing and Analysis Services, Contract Number: GS-07F-0243W, Contract Period: March 1, 2010 to February 28, 2015.
These contracts will create single laboratory validated methods for the quantitative determination of total silymarin content of milk thistle and of total curcuminoid content in turmeric. Having analytical tools to evaluate dietary supplement identity and purity is not only required under the new Current Good Manufacturing Practices (cGMPs) from the Food and Drug Administration (FDA), but is also a critical factor for assurance of public safety, developing and maintaining quality assurance standards in manufacturing and, ultimately, for meaningful efficacy testing of these products.
ChromaDex, in addition to its own expertise, will draw on the experience and knowledge of others in the botanical and dietary supplements industry to complete these two contracts. The goal of this work is to create methods that can be used to evaluate raw materials, extracts and finished products. Once completed, the methods developed under these contracts will be published.
Commenting on the announcement, Frank Jaksch, CEO and founder of ChromaDex, stated, "We are honored to be awarded these contracts by the NIH and ODS, as they provide further recognition of ChromaDex's phytochemical analytical expertise and the long history of collaboration between ChromaDex and the NIH in the area of dietary supplement reference standards and analytical testing. With the implementation of cGMPs now in full force, the industry needs to have robust analytical methods that they can rely on, such as the ones that will be developed by ChromaDex under the two contracts."